Log in to search using one of your social media accounts:

 

Researchers Discover Link between Gut Bacteria and the Effectiveness of Certain Cancer Drugs; Knowledge May Lead to New Types of Clinical Laboratory Tests

Microbiome is once again leading scientists toward a new understanding of how human gut bacteria can impact the efficacy and side-effects of certain cancer therapies Anatomic pathology researchers already know that a person’s genetics can affect the results of cancer treatments. Now it is becoming clear that a patient’s microbiome—which includes gut bacteria—may also impact […]
Source: Dark Daily - Category: Laboratory Medicine Authors: Tags: Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory News Laboratory Pathology Laboratory Testing Albert Einstein College of Medicine anatomic pathology beta-glucuronidase Source Type: news

Related Links:

Chloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondrial‑mediated apoptosis. Oncol Rep. 2018 Apr 12;: Authors: Liu L, Han C, Yu H, Zhu W, Cui H, Zheng L, Zhang C, Yue L Abstract Chloroquine (CQ) has been revealed to exhibit antitumor activity in several human tumors including lung cancer as mono‑ or add‑on therapy. The antitumor effect of CQ appears to depend on the tumor type, stage and genetic context. Few studies have focused on the mechanism concerning the antitumor effect of CQ monotherapy and the cause and effect relationship amo...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
I'm interested in pursuing Radiation Oncology, and was hoping to hear some thoughts on what the future will be like for Radiation Oncologists with some of the advancements in cancer therapy coming out (immunotherapy, for example). From my naive perspective, it seems like the future is pretty uncertain.
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums
(Cardiff University) A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe and nasty side effects associated with many cancer therapies, according to researchers at Cardiff University's School of Pharmacy and Pharmaceutical Sciences.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
This article serves to reemphasize the fallacies of carcinogenic risk and to highlight the possible benefits of low-dose exposure in hopes of invalidating the concerns of physicians, the diagnostic imaging technologists, and patient populations that are subject to diagnostic imaging and cancer radiation therapies.
Source: La Radiologia Medica - Category: Radiology Source Type: research
As the patent life ends or is close to ending on a number of novel biologic therapies for cancer therapy, the number of biosimilars in development has exploded, creating a new playing field important to providers, payers and patients [1]. What is a biosimilar? We are used to the concept of generic medications, where small molecules and simple chemicals are recreated, requiring only that the chemical structure and pharmacokinetics are the same as the original product. Biologics are large, complex molecules made in living cells, and owing to variations in production and post-translational modifications, even the branded or r...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE Abstract BACKGROUND: Thyroid dysfunction during tyrosine kinase inhibitor (TKI) cancer treatment is common, but predisposing risk factors have not been determined. Recommendations for monitoring patients treated with one or multiple TKI and in conjunction with other relevant cancer therapies could be improved. The study objective was to assess the risk factors for new thyroid dysfunction in TKI-treated previously euthyroid cancer patients. METHODS: A retrospective cohort study of patients with advanced nonthyroidal cancer ...
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Publication date: Available online 17 April 2018 Source:Pharmacological Research Author(s): Yan Ma, Chen Wang, Qi Zhang, Xia Peng, Ying Feng, Xianjun Meng The aim of this study was to assess the comparative efficacy and safety of polysaccharides from Auricularia auricula (Huaier) for patients with gastrointestinal cancers (GICs) through a systematic review and network meta-analysis. We performed a network meta-analysis to identify evidence from clinical trials. We searched databases for publications up to February 2018. The prespecified primary efficacy outcomes were clinical therapeutic effects, which included the treatm...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract Glucose transporter 6 (GLUT6) is a member of the facilitative glucose transporter family. GLUT6 is up-regulated in several cancers, but is not widely expressed in normal tissues. Previous studies have shown that GLUT6 knockdown kills endometrial cancer cells that express elevated levels of the protein. However, whether GLUT6 represents a viable anti-cancer drug target is unclear because the role of GLUT6 in normal metabolic physiology is unknown. Herein we generated GLUT6 knockout mice to determine how loss of GLUT6 affected whole body glucose homeostasis and metabolic physiology. We found that the mouse ...
Source: Am J Physiol Endocri... - Category: Endocrinology Authors: Tags: Am J Physiol Endocrinol Metab Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Laboratory Medicine | Pathology